转自：证券时报 人民财讯1月26日电，现货白银突破108美元/盎司，日内涨超5%。 转自：证券时报 人民财讯1月26日电，现货白银突破108美元/盎司，日内涨超5%。 ...

人民财讯1月26日电，1月26日，三大指数集体高开，上证指数高开0.21%，深证成指高开0.37%，创业 板指高开0.48%。盘面上，贵金属、光伏设备、有色金属、小金属、风电设备、HIT电池概念等板块开 盘活跃；房地产服务、航天航空、家用轻工、船舶制造、酿酒、半导体等板块开盘走低。 ...

Group 1 - The company, Dongpeng Beverage, will conduct a global offering of 40.89 million shares from January 26 to 29, with an expected listing on the Hong Kong Stock Exchange on February 3 [1] - The offering will consist of 10% for Hong Kong and 90% for international investors, with an additional 15% over-allotment option [1] - The maximum offer price is set at HKD 248.00 per share, with a trading unit of 100 shares [1] Group 2 - According to Frost & Sullivan, Dongpeng Beverage has ranked first in China's functional beverage market by sales volume for four consecutive years since 2021, with a projected market share of 26.3% in 2024 [1] - By retail value, the company is expected to be the second-largest functional beverage company in China in 2024, holding a market share of 23.0% [1] - The company's revenue growth is the highest among the top 20 listed soft drink companies globally [1] Group 3 - As of September 30, 2025, the company has established a comprehensive sales network covering over 4.3 million terminal sales points nationwide, achieving nearly 100% coverage of prefecture-level cities in China [1] - The company employs a sales team of over 7,500 individuals [1] - Dongpeng Beverage has pioneered the use of a "one code for one product" system and "five-code association" technology, creating a digital operation system that connects over 280 million consumers and interacts efficiently with over 4.3 million terminal sales points [1] Group 4 - Several well-known institutions, including Huang River Investment and JPMorgan Asset Management, have signed cornerstone investment agreements, with a total subscription amount of approximately USD 640 million [1] Group 5 - Assuming the over-allotment option is not exercised, the net fundraising amount is expected to be approximately HKD 9.994 billion [2] - The funds will primarily be used for capacity layout and supply chain upgrades (36%), brand building and consumer interaction (15%), national strategy and channel development (11%), overseas market expansion and acquisition opportunities (12%), digital construction (10%), product development and category expansion (6%), and working capital and general corporate purposes [2]

证券时报·数据宝统计，去年四季度共有2977只股票入围基金重仓股名单，以基金合计持股量占流通股 本的比例来看，共有14股基金持股比例超过20%，持股比例在10%~20%之间的有93只，持股比例 5%~10%的有230只，持股比例在1%~5%的有808只，1832只重仓股基金持股比例不足1%。 基金去年四季报显示，2977只股现身基金重仓股名单，其中基金持股比例超10%的共有107只。 基金去年四季度持股比例排名 | 002384 | 东山精密 | 346 | 31121.60 | 42.85 | 22.45 | 电子 | | --- | --- | --- | --- | --- | --- | --- | | 688796 | 百奥赛图 | 53 | 773.42 | 新进 | 21.55 | 医药生 | | | | | | | | 物 | | 688331 | 荣昌生物 | 56 | 3286.99 | -20.19 | 20.25 | 医药生 | | | | | | | | 物 | | 688068 | 热景生物 | 57 | 1838.58 | -5.30 | 19.83 | 医药生 | | | | ...

舜宇光学科技回购数量85.00万股，回购金额5415.15万港元，回购最高价为64.000港元，最低价为63.150 港元，年内累计回购金额8.20亿港元；华润燃气回购数量105.24万股，回购金额2280.22万港元，回购最 高价为22.000港元，最低价为21.480港元，年内累计回购金额4346.61万港元；碧桂园服务回购数量 210.00万股，回购金额1317.36万港元，回购最高价为6.330港元，最低价为6.210港元，年内累计回购金 额7408.18万港元。 以金额进行统计，1月23日回购金额最多的是舜宇光学科技，回购金额为5415.15万港元；其次是华润燃 气，回购金额为2280.22万港元；回购金额居前的还有碧桂园服务、快手-W等。回购数量上看，1月23 日回购股数最多的是碧桂园服务，当日回购量为210.00万股；其次是华润燃气、中国恒有源集团等，回 购数量分别为105.24万股、100.00万股。（数据宝） 1月23日港股公司回购一览 | 代码 | 简称 | 回购股数 | 回购金额（万 | 回购最高价 | 回购最低价 | 年内累计回购金额 | | --- | --- | --- | --- ...

个股方面，1月23日，有1460股获融资净买入，净买入金额在5000万元以上的有131股。其中，19股获融 资净买入额超2亿元。新易盛获融资净买入额居首，净买入5.7亿元；融资净买入金额居前的还有中国平 安、信维通信、中际旭创、江化微、紫金矿业、特变电工、金风科技、中国卫星等股。 Wind统计显示，1月23日，申万31个一级行业中有12个行业获融资净买入，其中，有色金属行业获融资 净买入额居首，当日净买入28亿元；获融资净买入居前的行业还有国防军工、银行、通信、非银金融、 交通运输等。 （文章来源：证券时报网） ...

Group 1 - The core business of the company is focused on addressing diseases caused by mitochondrial dysfunction, utilizing NAD+ in areas such as cardiovascular diseases, neurodegenerative diseases, reproductive health, and aging [1] - The flagship commercial drug of the company is Enadi (injectable coenzyme I), alongside other products including Qianrongmei, Tianshu, injectable nitroprusside, and 16 generic drugs covering four major therapeutic areas [1] - As of January 16, 2026, the company has 20 drugs in the production stage [1] Group 2 - The market size for mitochondrial medicine products in China is expected to grow rapidly, projected to increase from 17.9 billion RMB in 2024 to 308.1 billion RMB by 2035, with a compound annual growth rate of 29.5% [1]

东鹏饮料（605499）(09980.HK)发布公告，公司拟全球发售4088.99万股股份，其中香港发售股份408.90 万股，国际发售股份3680.09万股，另有613.34万股超额配股权。招股日期为1月26日至1月29日，最高发 售价248.00港元，每手买卖单位100股，入场费约25050.11港元。 全球发售预计募资总额为101.41亿港元，募资净额99.94亿港元，募资用途为用于未来三到五年内完善产 能佈局和推进供应链升级；用于未来三到五年内加强品牌建设和消费者互动；用于未来三到五年内拓展 海外市场业务，探索潜在投资及併购机会；用于未来三到五年内持续推进全国化战略，拓展、深耕和精 细化运营渠道网络；用于未来三到五年内加强各个业务环节的数字化建设；用于营运资金及一般企业用 途；用于未来三到五年内增强公司的产品开发能力，持续实现产品品类拓展。 公司引入Great China Motivation Fund Phase II L.P.、Fidelity Emerging Markets Discovery Fund及Fidelity Emerging Markets Value Advance Equit ...

依托"全景化"战略，艾隆科技已构建起覆盖医院内物资管控的全场景体系，不仅实现了发药机、分包机 等核心设备的国产替代，技术水平更达到国际领先水准，形成了从单一产品到整体解决方案的完善产品 线。其中，公司全系列发药机精准契合此次政策对追溯管理的要求，可在处方发出的同时自动完成追溯 码信息采集与关联，实现发药溯源全流程自动化，且发药速度零延迟，率先开创了追溯码采集无人化的 行业新范式。 市场分析指出，此次九部门政策从顶层设计层面明确了药品零售行业发展路径，行业数字化、集约化转 型需求将集中释放。艾隆科技作为兼具技术优势与场景覆盖能力的解决方案提供商，其产品与服务已得 到千余家医疗机构验证，在零售端的拓展潜力巨大。随着政策细则逐步落地，公司有望凭借先发优势抢 占市场份额，业绩增长动力将进一步增强。(齐和宁) 1月22日，商务部等九部门联合印发《关于促进药品零售行业高质量发展的意见》，从完善药事服务、 创新健康服务、优化行业结构等多维度明确发展方向，为药品零售行业规范化、数字化转型注入强劲动 力。作为医疗物资智慧管理领域领军企业，艾隆科技(688329.SH)凭借在智慧药房、智慧病区、智慧仓 储、药学信息等领域的深厚积 ...

（原标题：现货黄金突破5060美元/盎司） 人民财讯1月26日电，现货黄金突破5060美元/盎司，涨超1.5%。 ...